On the one hand, DKK3 has been shown to act as a tumor suppressor in many cancers and DKK3 overexpression has been investigated as a therapeutic target including a current phase I trial of adenovirus-vector-mediated DKK3 overexpression in liver metastases of hepatocellular carcinoma. Here, DKK3 is linked to cancer.